Publication

Impact of atrial fibrillation on the risk of major adverse cardiac events following coronary revascularisation

Downloadable Content

Persistent URL
Last modified
  • 06/25/2025
Type of Material
Authors
    Richard G Jung, University of Ottawa Heart InstituteOmar Abdel-Razek, University of Ottawa Heart InstitutePietro Di Santo, University of Ottawa Heart InstituteTaylor Gillmore, University of OttawaCameron Stotts, University of OttawaDwipen Makwana, University of OttawaJoelle Soriano, University of OttawaRobert Moreland, University of Ottawa Heart InstituteLouis Verreault-Julien, Emory UniversityCheng Yee Goh, University of Ottawa Heart InstituteSimon Parlow, University of Ottawa Heart InstituteCaleb Sypkes, University of OttawaDaniel F Ramirez, University of Ottawa Heart InstituteMouhannad Sadek, University of Ottawa Heart InstituteVincent Chan, University of Ottawa Heart InstituteHadi Toeg, University of Ottawa Heart InstituteTrevor Simard, Mayo Clinic, RochesterMichael PV Froeschl, University of Ottawa Heart InstituteMarino Labinaz, University of Ottawa Heart InstituteBenjamin Hibbert, University of Ottawa Heart Institute
Language
  • English
Date
  • 2022-09-23
Publisher
  • BMJ Publishing Group
Publication Version
Copyright Statement
  • © Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.
License
Final Published Version (URL)
Title of Journal or Parent Work
Volume
  • 9
Issue
  • 2
Grant/Funding Information
  • RGJ was funded by the Vanier CIHR Canada Graduate Scholarship. The authors would like to thank all the collaborators and CAPITAL Research Group for all their support and guidance for the completion of the project.
Supplemental Material (URL)
Abstract
  • Objective Atrial fibrillation (AF) remains a highly prevalent arrhythmia with significant burden on morbidity and mortality. The impact of AF in the revascularised population remains incompletely described. Given the high prevalence of AF in the revascularised population, we sought to evaluate the incidence and prognosis in patients with pre-existing and new-onset AF following revascularisation. Methods We used the University of Ottawa Heart Institute Revascularisation Registry to identify patients who underwent revascularisation between August 2015 and March 2020, who were prospectively followed for an average of one year. We conducted a retrospective cohort study analysing the association between AF and clinical outcomes. The primary outcome of interest was 1-year major adverse cardiac events (MACE) defined as a composite of death, myocardial infarction, unplanned revascularisation and cerebrovascular accidents. Moreover, secondary outcomes include the individual components of MACE and bleeding. Results A total of 6704 patients underwent revascularisation and completed 1-year clinical follow-up. Median time to follow-up was 12.8 (IQR 11.2–15.9) months. One-year MACE occurred in 166 (21.8%) and 683 (11.5%) patients in AF and non-AF groups, respectively (adjusted HR, 1.61; 95% CI 1.29 to 2.01; p<0.0001). AF was independently predictive of 1-year mortality, myocardial infarction, unplanned revascularisation, cerebrovascular accident and bleeding. Within 1 year, 299 (4.5%) episodes of new-onset AF was observed. New-onset AF following revascularisation was also associated with 1-year MACE, mortality, myocardial infarction, cerebrovascular accident and unplanned revascularisation. Conclusions Preprocedural and new-onset AF following revascularisation remains highly predictive 1-year MACE. AF should be considered in addition to traditional risk factors for adverse outcomes following revascularisation.
Author Notes
Keywords
Research Categories
  • Health Sciences, Medicine and Surgery

Tools

Relations

In Collection:

Items